Zynga Sales on the DECLINE and 4 New Stock Analyses To Notice Now
Ecolab Inc. (NYSE:ECL): Following meetings with management, Deutsche Bank stated that it has increased confidence that Ecolab is still on track to meet its $3.00 earnings per share target for 2013. The firm keeps a Buy rating and a $75 price target on the stock.
Valeant Pharmaceuticals International (NYSE:VRX) price target has been increased by Jefferies due to its pending takeover of Medicis (NYSE:MRX), and it maintains a Buy rating on the stock. The firm names Valeant as its number one pick.
Zynga, Inc. (NASDAQ:ZNGA): According to Piper Jaffray, August NPD video game software sales fell 9 percent year-over-year, which it notes is a directional positive compared to the down 27 percent year-to-date results. Piper continues to be encouraged by Electronic Arts (NASDAQ:EA) and Activision Blizzard’s (NASDAQ:ATVI) holiday game slate.
Smith & Wesson Holding Corporation (NASDAQ:SWHC) estimates and price targets have been increased by Benchmark Co. due to the company’s better than expected Q1 results and raised guidance. The firm maintains a Buy rating on the stock.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Leerink stated that it left meetings with BioMarin management with an increased conviction that the company possesses various attractive growth opportunities. The firm predicts that BioMarin will provide positive updates regarding PEG-PAL and BMN-111 prior to the end of September, and it states that the stock should be a core holding for biotech investors.
Don’t Miss: Will This Apple Move Destroy Pandora?
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>